Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.47 |
| ▸ | DDB1 | Q16531 | 8/20 | 0.47 |
| ▸ | CCNC | P24863 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.43 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.43 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.43 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.43 |
| ▸ | RAF1 | P04049 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.40 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | IL2 | P60568 | 1/20 | 0.38 |
| ▸ | ITK | Q08881 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22951134 | 1.00 | CRBN (0.47) | CRBNDDB1CCNCCDK8IRAK1 | |
| SCHEMBL22951135 | 0.95 | CRBN (0.48) | CRBNDDB1CCNCCDK8IRAK1 | |
| SCHEMBL24299444 | 0.91 | CRBN (0.54) | CRBNDDB1GPR119 | |
| SCHEMBL22291403 | 0.86 | CRBN (0.57) | CRBNDDB1CCNCCDK8IRAK1 | |
| SCHEMBL29648407 | 0.86 | CRBN (0.57) | CRBNDDB1CCNCCDK8IRAK1 | |
| SCHEMBL24501945 | 0.86 | CRBN (0.57) | CRBNDDB1CCNCCDK8IRAK1 | |
| SCHEMBL31620804 | 0.86 | CRBN (0.57) | CRBNDDB1CCNCCDK8IRAK1 | |
| SCHEMBL24299447 | 0.85 | CRBN (0.55) | CRBNDDB1GPR119 | |
| SCHEMBL29919803 | 0.84 | SIGMAR1 (0.45) | — | |
| SCHEMBL30906264 | 0.83 | ESR1 (0.53) | CRBNDDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590079-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20220289711-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590079-B2 | Compounds and uses thereof | PSMB6, PSMC4, PSMB2 | CRBN 16/4885DDB1 736/4885CCNC 604/4885 |
| US-20220289711-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | CRBN 179/4885DDB1 987/4885CCNC 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.